Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

Phase

N/A

Condition

Digestive System Neoplasms

Vaccines

Stomach Cancer

Treatment

SOX plus PD-1 inhibitor

Gastroscopic biopsy

Clinical Study ID

NCT06202781

scgc1

Ages 18-70
All Genders

Study Summary

The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are:

Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer
Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses

Eligibility Criteria

Inclusion

Inclusion Criteria:

Non-bedridden, aged 18 to 70 years old;
Eastern Cooperative Oncology Group (ECOG) score is 0 to 1;
Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1;
Advanced gastric cancer;
Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab orsintilimab

Exclusion

Exclusion Criteria:

History of other malignant diseases in the last 5 years;
Prior chemotherapy, radiotherapy or immunotherapy;
Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.

Study Design

SOX plus PD-1 inhibitor

July 01, 2022

July 31, 2024

Connect with a study center

Chinese PLA General Hospital
Beijing, Beijing 100853
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.